Paper11834837
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor.
Di Croce L and 11 others. Science, 2002. Cited by 606 papers, by iCite.
Cite this record
ConductScience Library. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Papers, record 11834837. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11834837
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor.
- PubMed
Topics29
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Azacitidine | Major topic |
| DNA (Cytosine-5-)-Methyltransferases | Major topic |
| DNA Methylation | Major topic |
| Gene Silencing | Major topic |
| Neoplasm Proteins | Major topic |
| Oncogene Proteins, Fusion | Major topic |
| Promoter Regions, Genetic | Major topic |
| Receptors, Retinoic Acid | Major topic |
| Binding Sites | |
| Cell Differentiation | |
| Cell Line | |
| Cell Nucleus | |
| Cell Transformation, Neoplastic | |
| Cloning, Molecular | |
| CpG Islands | |
| DNA (Cytosine-5-)-Methyltransferase 1 | |
| DNA Methyltransferase 3A | |
| Decitabine | |
| Exons | |
| Gene Expression | |
| Histone Deacetylases | |
| Humans | |
| Leukemia, Promyelocytic, Acute | |
| Mutation | |
| Recombinant Fusion Proteins | |
| Transcription Factors | |
| Tretinoin | |
| Tumor Cells, Cultured | |
| Zinc |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 11834787 | Cancer research. Leukemia protein spurs gene silencing. | https://conductscience.org/library/papers/11834787 | PubMed |
| Comment in | 12229925 | Cancer epigenetics and methylation. | https://conductscience.org/library/papers/12229925 | PubMed |
Cited by271
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 606 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42856463 | Tumor suppressor-like mutations mark a dosage-constrained dependency in leukemia. | bioRxiv | 2026 | https://conductscience.org/library/papers/42856463 | PubMed |
| 39528729 | The N-terminal region of DNMT3A engages the nucleosome surface to aid chromatin recruitment. | EMBO Rep | 2024 | https://conductscience.org/library/papers/39528729 | PubMed |
| 39006906 | Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review). | Mol Clin Oncol | 2024 | https://conductscience.org/library/papers/39006906 | PubMed |
| 38895633 | Traditional Chinese medicine for acute myelocytic leukemia therapy: exploiting epigenetic targets. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38895633 | PubMed |
| 38696033 | Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors. | Curr Treat Options Oncol | 2024 | https://conductscience.org/library/papers/38696033 | PubMed |
| 38628758 | Epigenetic regulation of FOXI2 promotes clear cell renal cell carcinoma progression. | Heliyon | 2024 | https://conductscience.org/library/papers/38628758 | PubMed |
| 37569414 | The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37569414 | PubMed |
| 37568827 | YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37568827 | PubMed |
| 37509198 | The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37509198 | PubMed |
| 36630129 | Characterizing crosstalk in epigenetic signaling to understand disease physiology. | Biochem J | 2023 | https://conductscience.org/library/papers/36630129 | PubMed |
| 36460706 | DNMT3B overexpression downregulates genes with CpG islands, common motifs, and transcription factor binding sites that interact with DNMT3B. | Sci Rep | 2022 | https://conductscience.org/library/papers/36460706 | PubMed |
| 36060265 | 5-methylcytosine turnover: Mechanisms and therapeutic implications in cancer. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/36060265 | PubMed |
| 35999358 | Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis. | Cancer Gene Ther | 2023 | https://conductscience.org/library/papers/35999358 | PubMed |
| 35902872 | RUNX1T1 function in cell fate. | Stem Cell Res Ther | 2022 | https://conductscience.org/library/papers/35902872 | PubMed |
| 35808817 | mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma. | J Int Med Res | 2022 | https://conductscience.org/library/papers/35808817 | PubMed |
| 35450883 | In vivo temporal resolution of acute promyelocytic leukemia progression reveals a role of Klf4 in suppressing early leukemic transformation. | Genes Dev | 2022 | https://conductscience.org/library/papers/35450883 | PubMed |
| 35440061 | Pioneer transcription factors are associated with the modulation of DNA methylation patterns across cancers. | Epigenetics Chromatin | 2022 | https://conductscience.org/library/papers/35440061 | PubMed |
| 35399865 | PML nuclear body biogenesis and oligomerization-driven leukemogenesis. | Blood Sci | 2020 | https://conductscience.org/library/papers/35399865 | PubMed |
| 35280824 | All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism. | Front Oncol | 2022 | https://conductscience.org/library/papers/35280824 | PubMed |
| 35080973 | Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity. | Sci Adv | 2022 | https://conductscience.org/library/papers/35080973 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DNMT1 | 1786 | PubTator's text mining | https://conductscience.org/library/genes/1786 | NCBI Gene |
| DNMT3A | 1788 | PubTator's text mining | https://conductscience.org/library/genes/1788 | NCBI Gene |
| RARB | 5915 | PubTator's text mining | https://conductscience.org/library/genes/5915 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11834837
GET https://conductscience.org/api/papers/v1/11834837/cited_by?page=2